Johnson & Johnson 1-dose Shot Prevents COVID-19, But Less Than Some Others

January 29, 2021by Lauran Neergaard and Linda A. Johnson, Associated Press
This Sept. 2020 photo provided by Johnson & Johnson shows the investigational Janssen COVID-19 vaccine. Johnson & Johnson's long-awaited COVID-19 vaccine appears to protect against symptomatic illness with just one shot – not as strong as some two-shot rivals but still potentially helpful for a world in dire need of more doses. Johnson & Johnson said Friday, Jan. 29, 2021 that in the U.S. and seven other countries, the first single-shot vaccine appears 66% effective overall at preventing moderate to severe COVID-19. It was more protective against severe symptoms, 85%. (Cheryl Gerber/Johnson & Johnson via AP)

Johnson & Johnson’s long-awaited vaccine appears to protect against COVID-19 with just one shot – not as strong as some two-shot rivals but still potentially helpful for a world in dire need of more doses.

J&J said Friday that in the U.S. and seven other countries, the single-shot vaccine was 66% effective overall at preventing moderate to severe illness, and much more protective — 85% — against the most serious symptoms.

There was some geographic variation. The vaccine worked better in the U.S. — 72% effective against moderate to severe COVID-19 – compared to 57% in South Africa, where it was up against an easier-to-spread mutated virus.

“Gambling on one dose was certainly worthwhile,” Dr. Mathai Mammen, global research chief for J&J’s Janssen Pharmaceutical unit, told The Associated Press.

With vaccinations off to a rocky start globally, experts had been counting on a one-dose vaccine that would stretch scarce supplies and avoid the logistics nightmare of getting people to return for boosters.

But with some other competing vaccines shown to be 95% effective after two doses, at question is whether somewhat less protection is an acceptable tradeoff to get more shots in arms quickly.

The company said within a week, it will file an application for emergency use in the U.S., and then abroad. It expects to supply 100 million doses to the U.S. by June, and expects to have some ready to ship as soon as authorities give the green light.

These are preliminary findings from a study of 44,000 volunteers that isn’t completed yet. Researchers tracked illnesses starting 28 days after vaccination – about the time when, if participants were getting a two-dose variety instead, they would have needed another shot.

After day 28, no one who got vaccinated needed hospitalization or died regardless of whether they were exposed to “regular COVID or these particularly nasty variants,” Mammen said. When the vaccinated did become infected, they had a milder illness.

Defeating the scourge that has killed more than 2 million people worldwide will require vaccinating billions, and the shots being rolled out in different countries so far all require two doses a few weeks apart for full protection. Early data is mixed on exactly how well all the different kinds work, but shots made by Pfizer and Moderna appear to be about 95% protective after the second dose.

But amid shortages, some countries have advised delaying the second dose of certain vaccines with little data on how that would affect protection.

All COVID-19 vaccines train the body to recognize the new coronavirus, usually by spotting the spikey protein that coats it. But they’re made in very different ways.

J&J’s shot uses a cold virus like a Trojan horse to carry the spike gene into the body, where cells make harmless copies of the protein to prime the immune system in case the real virus comes along.

Rival AstraZeneca makes a similar cold virus vaccine that requires two doses. Both the AstraZeneca and J&J vaccines can be stored in a refrigerator, making them easier to ship and to use in developing countries than the frozen kind made by Pfizer and Moderna.

It’s not clear exactly how well the AstraZeneca version, being used in Britain and several other countries, works. Tests in Britain, South Africa and Brazil suggested two doses are about 70% effective although there are questions about how much protection older adults get. An ongoing U.S. study may provide more information.

J&J said its vaccine works consistently in a broad range of people: A third of participants were over age 60, and more than 40% had other illnesses putting them at risk of severe COVID-19, including obesity, diabetes and HIV.

J&J said the vaccine is safe, with reactions similar to other COVID-19 shots such as fever that occur when the immune system is revved up.

While it released few details, the company said there were no serious allergic reactions. But occasionally other COVID-19 vaccines trigger such reactions, which can be reversed if promptly treated – and authorities have warned people to be on the lookout regardless of which type of vaccine is used.

J&J had hedged its bets with a study of a two-dose version of its vaccine, which is still underway.

Friday’s interim results come on the heels of another vaccine in final testing. Novavax reported this week that its vaccine appears 89% effective in a U.K. study and that it also seems to work — though not as well — against new mutated versions of the virus circulating in Britain and South Africa. A larger study in the U.S. and Mexico is still enrolling volunteers.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

In The News

Health

Voting

Health

Transportation Official Says Security is Good for Airline Travel
Travel
Transportation Official Says Security is Good for Airline Travel
May 6, 2021
by Tom Ramstack

WASHINGTON -- A top Transportation Security Administration official gave an upbeat outlook to Congress Wednesday for a return to normal travel habits as the COVID-19 pandemic subsides in the United States. He said the agency would continue its pandemic health and safety procedures but did not... Read More

DOJ to Appeal Federal Judge Ruling on CDC Eviction Moratorium
Litigation
DOJ to Appeal Federal Judge Ruling on CDC Eviction Moratorium
May 6, 2021
by Reece Nations

WASHINGTON — After a federal judge ruled on Wednesday the Centers for Disease Control and Prevention moratorium on evictions exceeded the agency's authority, the Department of Justice announced it would appeal the decision. U.S. District Court Judge Dabney Friedrich authored the 20-page opinion accompanying the ruling.... Read More

Women in the Rockies Use Horses for Healing
Mental Health
Women in the Rockies Use Horses for Healing
May 5, 2021
by Alexa Hornbeck

About 6 miles outside of a tiny town called Granby, Colo.,  is a little ranching community called C Lazy U Ranch nestled 8,000 feet high aside the cusp of the towering Rocky Mountains.  Entering the ranch is a dusty dirt road that leads to a vista... Read More

US Backs Waiving Intellectual Property Rules on Vaccines
Health
US Backs Waiving Intellectual Property Rules on Vaccines
May 5, 2021
by Dan McCue

WASHINGTON - The Biden administration announced Wednesday that it will support efforts to waive intellectual property protections for COVID-19 vaccines in an effort to speed the end of the pandemic. United States Trade Representative Katherine Tai announced the government’s position in written statement, amid World Trade... Read More

Parents Excited Over Prospect of Virus Shots for Children
Health
Parents Excited Over Prospect of Virus Shots for Children

MISSION, Kan. (AP) — After more than a year of fretting over her 13-year son with a rare liver disease, Heather Ousley broke into tears when she learned that he and millions of other youngsters could soon be eligible for the COVID-19 vaccine. "This day is... Read More

How the Pandemic Is Shaping Policies for Smoke-Free Air in Casinos
Health
How the Pandemic Is Shaping Policies for Smoke-Free Air in Casinos
May 5, 2021
by Alexa Hornbeck

Nathan Moose, a member of the Oglala Sioux Tribe, developed permanent lung damage equivalent to that of a heavy smoker, despite never having smoked a day in his life.   Moose was an employee of a casino for 11 years that allowed indoor smoking, and in 2013... Read More

News From The Well
scroll top